Author/Authors :
Shah, Ankoor R Department of Ophthalmology - Oakland University William Beaumont School of Medicine - Beaumont Eye Institute, Royal Oak, MI, USA , Xi, Mengqiao Department of Ophthalmology - Oakland University William Beaumont School of Medicine - Beaumont Eye Institute, Royal Oak, MI, USA , Abbey, Ashkan M Department of Ophthalmology - Oakland University William Beaumont School of Medicine - Beaumont Eye Institute, Royal Oak, MI, USA , Yonekawa, Yoshihiro Department of Ophthalmology - Oakland University William Beaumont School of Medicine - Beaumont Eye Institute, Royal Oak, MI, USA , Faia, Lisa J Department of Ophthalmology - Oakland University William Beaumont School of Medicine - Beaumont Eye Institute, Royal Oak, MI, USA , Hassan, Tarek S Department of Ophthalmology - Oakland University William Beaumont School of Medicine - Beaumont Eye Institute, Royal Oak, MI, USA , Ruby, Alan J Department of Ophthalmology - Oakland University William Beaumont School of Medicine - Beaumont Eye Institute, Royal Oak, MI, USA , Wolfe, Jeremy D Department of Ophthalmology - Oakland University William Beaumont School of Medicine - Beaumont Eye Institute, Royal Oak, MI, USA
Abstract :
Purpose: To determine the efficacy of an intravitreal dexamethasone implant (IDI) for diabetic macular
edema (DME) in vitrectomized eyes.
Methods: This interventional retrospective consecutive case series included vitrectomized eyes undergoing
IDI placement for treatment of recalcitrant DME between June 2011 and June 2014. All patients had previously
received anti‑VEGF therapy (ranibizumab or bevacizumab). Primary endpoints were changes in visual
acuity (VA) and central retinal thickness (CRT) from baseline values one month after device implantation.
Secondary endpoints were VA and CRT changes at 3 months.
Results: A total of 8 eyes of 8 patients met the inclusion criteria. One month after IDI placement, there
was a significant (p = 0.01) improvement in VA from 0.79 ± 0.52 logMAR (20/123 Snellen equivalent) to
0.64 ± 0.55 logMAR (20/88), meanwhile CRT improved from 455.75 ± 123.19 to 295.00 ± 90.39 μm (p = 0.02).
These findings persisted at 3 months.
Conclusion: In vitrectomized eyes previously treated with anti‑VEGF agents for recalcitrant DME,
implantation of the IDI appears to be efficacious in improving VA and CRT at 1‑month with the observed
benefits persisting for at least for 3 months.
Keywords :
Diabetic Macular Edema , Dexamethasone , Ozurdex , Vitrectomy
